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Abstract 
 
From February 1995 through October 1996, 25 patients with metastatic 
colorectal 
cancer showing a clinical resistance to 5-fluorouracil (5-FU) entered 
this 
study. Thirteen received oxaliplatin alone and 12 received it in 
combination 
with 5-FU. Oxaliplatin was administered at 130 mg/m2 over a 2-hour 
infusion 
every 3 weeks, alone or added either to 5-FU as a continuous infusion at 
200 
mg/m2 to 300 mg/m2 (six patients) or to a 5-FU bolus, 375 mg/m2, plus 
leucovorin, 
100 mg/m2, daily for 5 days every 3 weeks (6 patients). 
 
Eighty-six of 98 administered cycles were evaluable for toxicity (47 for 
oxaliplatin plus 5-FU and 39 for oxaliplatin alone). Hematologic toxicity 
was 
mild, occurring as grade 2 leukopenia in 23% of the cycles of 5-FU and 
oxaliplatin and in 5% of the cycles of oxaliplatin alone. The most common 
toxicity was neurologic (grade 1 to 2 in 60%-6% of the cycles of the 
combination, 
respectively, and 68%-10% of oxaliplatin given alone) as hand-foot 
paresthesia 
or hypersensitivity to cold. No grade 4 toxicity was reported and only 
three 
patients in the 5-FU group developed grade 3 diarrhea. Grade 2 nausea and 
vomiting occurred in 33% of the cycles when both drugs were given and in 
15% 
when oxaliplatin was administered alone. 
 
The combination of oxaliplatin and 5-FU induced four partial remissions 
(33%; 
95% confidence interval, 6%-60%), whereas eight patients of the whole 
group had 
stable disease. No response occurred when oxaliplatin was administered as 
a 
single agent. The results of this study confirm the antitumor activity of 
oxaliplatin when added to 5-FU in patients who have metastatic colorectal 
cancer 
previously refractory to 5-FU. The possible therapeutic synergy with 5-FU 
was 
not accompanied by increased toxicity. 
 
---------------------------------------------- 
 
In the past 30 years, the chemotherapeutic approach to advanced 
colorectal 
cancer has remained one of the major challenges for medical oncologists. 
Fluorinated pyrimidines, especially 5-fluorouracil (5-FU), have been the 
main 
active drugs.1 More recently, several randomized studies have provided 
the 
evidence that biochemical modulation of 5-FU with leucovorin confers a 
superior 
response rate when compared with the administration of 5-FU alone.1,2 
Conversely, 
the optimal dose, schedule, and route of administration of the 
combination have 
not been established. Complete response rates remain disappointingly low, 
and 
the improvement of the median survival appears to be small. Oxaliplatin 
is a new 
third-generation platinum complex that has no renal toxicity and minimal 
hematologic toxicity.3 The main site of action of oxaliplatin is DNA, 
producing 
adducts that block both replication and transcription. In contrast to 
cisplatin-for 
which the kinetics of binding with DNA are biphasic, with one rapid phase 
of 
approximately 15 minutes and a slower terminal phase lasting 4 to 8 
hours-the 
DNA binding of oxaliplatin is complete after a maximum of 15 minutes. 
Preliminary 
studies suggest that the combination of 5-FU and oxaliplatin is 
synergistic 
against L1210 leukemia transplanted into mice.4,5 
 
Phase I clinical trials recommended a dose of 130 mg/m2 given by 2-hour 
infusion 
and repeated every 3 weeks 6 for further phase II studies. Phase II-III 
trials 
demonstrated a certain degree of activity in advanced colorectal cancer. 
When 
oxaliplatin alone was given to patients refractory to 5-FU, the reported 
response rate was approximately 10%7; when given in combination with 5-FU 
and 
leucovorin, the response was 28% to 53%.8-10 
 
These encouraging results prompted us to use oxaliplatin alone or in 
combination 
with 5-FU and leucovorin in advanced colorectal cancer patients who had 
disease 
refractory to 5-FU-based chemotherapy. 
 
PATIENTS AND METHODS 
 
Patients 
 
From February 1995 through October 1996, 25 patients who had advanced 
colorectal 
cancer were treated in an outpatient setting at the Division of Medical 
Oncology, European Institute of Oncology, Milan, Italy. Twenty-three 
patients 
were pretreated and progressing while on or within 6 months of the last 
5-FU-containing chemotherapy; two patients progressed more than 6 months 
after 
the last 5-FU regimen. Criteria for inclusion also required adequate bone 
marrow 
and renal function, age younger than 75 years, performance status higher 
or 
equal to 2 according to the Eastern Cooperative Oncology Group scale, and 
measurable disease according to the World Health Organization criteria. 
Patient 
characteristics are shown in Table 1. 
 All patients had undergone surgical resection of the primary lesion (7 
rectal 
carcinoma, 18 colon), with histologic proof of cancer. Primary staging at 
surgical diagnosis was performed according to Dukes criteria, with 10 
patients 
assigned to stage D, 10 to stage C, three to stage B, one to stage A, and 
one to 
unknown. 
 
Metastatic sites of disease included liver in 20 patients, lung in 13 
patients, 
soft tissues in five patients, and other sites in seven patients; 
patients who 
had single or multiple sites of metastatic disease were treated as 
detailed in 
Table 1. 
 
Overall, 24 patients were evaluable for activity and for toxicity because 
one 
patient was lost to follow-up after one cycle. 
 
Eligible patients underwent a complete staging of metastatic sites using 
radiographs, computed tomographic scanning or ultrasound as indicated, 
and 
physical examination. Weight, height, complete blood count, liver and 
renal 
function, carcinoembryonic antigen and CA19.9 were also determined. 
 
Toxicity was assessed for each cycle, according to the World Health 
Organization 
scale. Informed written consent was obtained according to procedures set 
forth 
by the ethical committee of the institute. 
 
Drug Administration 
 
Oxaliplatin was supplied by Debiopharm (Lausanne, Switzerland) as a 
freeze-dried 
powder for infusion in vials containing 50 mg or 100 mg of the drug. 
Oxaliplatin 
was reconstituted in 5% glucose solution or water in the original vial 
for 
injection and diluted in 250 ml of 5% glucose solution for the infusion. 
The 
drug was administered at 130 mg/m2 as an intravenous infusion over 2 
hours every 
21 days. 5-fluorouracil was purchased from F. Hoffmann-La Roche Ltd. 
(Basel, 
Switzerland) as 5-ml vials containing 250 mg of the drug. It was 
administered as 
a bolus intravenously at 375 mg/m2 over 5 days with leucovorin 100 mg/m2 
or by 
continuous intravenous infusion at 200 mg/m2/day up to 300 mg/m2/day 
through a 
central venous catheter with a Pharmacia CADD-Plus pump. 
 
Oxaliplatin was added to 5-FU in those patients who were progressing 
while on 
5-FU and were tolerating the treatment well. 
 Response Assessment 
 
Responses were assessed according to World Health Organization criteria 
every 
two or three cycles. Patients who had stable disease continued 
oxaliplatin until 
tumor progression or until a maximum of nine cycles. Patients who 
achieved a 
partial response continued for at least two cycles after response 
stabilization. 
Similarly, in cases of complete response, patients were to receive at 
least two 
additional cycles of oxaliplatin. In contrast, patients who had 
progressive 
disease were immediately taken off study. All responses were reassessed 
after 
two or three additional cycles of therapy. 
 
Statistical Analysis 
 
The duration of response and the time to progression were both calculated 
from 
the first drug administration to disease progression. The comparison of 
toxicity 
results between different groups was performed using the chi-square test. 
The t 
test for paired data was used for different group comparisons of 
continuous 
measurements performed at different intervals before, during, and after 
therapy. 
The reported values are for two-tailed tests. 
 
RESULTS 
 
Thirteen patients were treated with oxaliplatin as a single agent; in the 
other 
12 patients, it was added in combination to the ongoing 5-FU regimen. 
Among 
these 12 patients, six received 5-FU as a continuous infusion and six as 
a 
intravenous bolus plus leucovorin. 
 
Globally, 98 cycles have been administered. To date, 86 are evaluable for 
toxicity: 39 cycles of oxaliplatin alone and 47 of the combination (29 
with 
bolus 5-FU and 22 with 5-FU continuous infusion). Patients received a 
median of 
three cycles (range, 1-9 cycles): three for the oxaliplatin alone and 
four for 
the combination. The dose of oxaliplatin was reduced by 25% in four 
cycles 
(three patients), and the median interval between cycles was 21 days 
(range, 
21-71 days). 
 
Toxicities 
 
The most common toxicities for oxaliplatin and 5-FU are shown in Table 2. 
Leukopenia was mild, occurring in 23% of the cycles as grade 2; no grade 
3 or 4 
leukopenia was observed. Grade 2 neutropenia also was reported in 21% of 
the 
cycles. Grade 1 thrombocytopenia occurred in 9% of the cycles and grade 2 
in 6%. 
Only two patients experienced grade 2 mucositis (4% of the cycles) and 
grade 3 
diarrhea was present in three patients (6% of the cycles). Typical 
oxaliplatin 
neurologic toxicity, characterized by peripheral or pharyngolaryngeal 
dysesthesia 
caused and aggravated by cold and distal paresthesia, are reported as 
grade I 
(mild) in 60% of the cycles and grade 2 (intermediate) in 6% of the 
cycles. Only 
one patient had grade 2 renal toxicity in one cycle (2%). Nausea and 
vomiting 
occurred as grade 2 in 33% of the cycles. Alopecia was uncommon. 
 
Considering the two different schedules of administration of 5-FU, the 
toxicities are similar in both schedules and without significant 
difference 
(Table 3). 
 
The most common toxicities for oxaliplatin alone are shown in Table 4. 
Leukopenia occurred rarely-only in seven cycles (8%)-and the worst was 
grade 3 
in one cycle (3%). In only six cycles (15%) did we observed grade 1 
neutropenia. 
Grade 1 thrombocytopenia occurred in 13% of the cycles and grade 2 in 3% 
(1 
cycle). Mucositis was mild also, occurring as grade 1 in only two cycles 
(5%), 
whereas grade 2 diarrhea was present in 10% of the cycles. Neurologic 
toxicity 
was reported as grade 1 (mild) in 68% of the cycles and as grade 2 
(intermediate) 
in 10% of the cycles. Renal toxicity was absent. Nausea and vomiting 
occurred as 
grade 2 in 15% of the cycles. Alopecia was uncommon. 
 
Antitumor Activity 
 
The combination of oxaliplatin and 5-FU induced four partial remissions 
(33%; 
95% confidence interval, 6%-60%) lasting, respectively, 6.9, 4.4, 7.9, 
and 6.9 
months. No complete responses were observed and four (33%) of the 
patients had 
stable disease, with a median duration of 4 months (range, 3.2-4.5 
months; see 
Table 4). Responding patients had visceral disease involving liver and 
lung in 
three patients and pelvis and lung in one patient. Of the responding 
patients, 
two were treated with 5-FU continuous infusion and two with 5-FU bolus 
plus 
leucovorin over 5 days. All were progressing while on 5-FU or within 6 
months, 
and they all received bolus 5-FU as a pretreatment. Two of these patients 
were 
progressing while on 5-FU continuous infusion-given as a second-line 
treatment-when 
oxaliplatin was added (Table 5). The response to previous bolus 5-FU plus 
leucovorin was not assessable for the four responding patients because 
they 
received the treatment in an adjuvant setting (n = 2) or after liver 
metastases 
resection (n = 2). See Table 6 for charactertistics of responding 
patients. 
 
When oxaliplatin was administered as a single agent, no response was 
observed 
and four instances of stable disease were reported (33%); the median 
duration 
was 7.8 months (range, 3.3-11.3 months). The median time on study was 3 
months 
(range, 1-8 months) and it was significantly lower (p = 0.07; t test) 
when 
oxaliplatin was given alone (2 months) and compared with the combination 
(4 
months). The median time to response was 3.6 months (range, 2-4.6 months) 
and 
the median time to progression was 3 months (range, 1-11 months). 
Patients 
treated with the combination had a median time to progression of 4 
months, 
compared with oxaliplatin alone, for which the time to progression was 2 
months, 
but this difference is not significant. 
 
DISCUSSION 
 
No treatment can be considered to be standard for metastatic colorectal 
cancer 
because cures are rarely expected. Despite the many new promising 
compounds for 
cancer treatment that are available, only a few of them have some 
activity in 
this disease. 
 
Metaanalysis reveals a better response rate for the combination of 5-FU 
plus 
leucovorin, compared with 5-FU alone, with no difference on 
survival.11,12 In 
the last few years, low-dose 5-FU as a continuous infusion for many weeks 
has 
been described as a more rational, effective, and less toxic schedule for 
this 
drug.13 
 
Actually, it is a common practice to treat patients who have metastatic 
disease 
with 5-FU plus leucovorin as first-line therapy and to consider 5-FU 
continuous 
infusion as a second-line regimen for patients who have progressive 
disease 
after an initial response. The role of second-line therapy in colorectal 
cancer 
is doubtful, however, and patients progressing while on treatment are 
those less 
likely to benefit from further chemotherapy. 
 
In our study of pretreated metastatic colon cancer patients, 33% 
benefited from 
treatment with oxaliplatin and 5-FU plus or minus leucovorin without 
showing a 
significant toxicity. We stress the fact that all the responding patients 
treated in our series were progressing while on 5-FU or within 6 months 
of 5-FU 
therapy. This may be clinical evidence of synergistic activity of 
oxaliplatin 
and 5-FU, as shown in in vitro studies.4 Similar results have been 
reported in a 
phase II study using the same combination of drugs, in which the response 
rate 
was 25%.4 The activity of this combination is even higher when 
oxaliplatin is 
chronomodulated with 5-FU and leucovorin, displaying a 58% response rate 
in 
pretreated metastatic colon cancer patients.8 
 
Oxaliplatin has low toxicity; grade 2 emesis occurred in 33% of the 
cycles of 
the combination and in 15% when it was given as a single agent. 
 
Our series is too small to show a significant advantage in terms of 
survival for 
the addition of oxaliplatin. In the literature, median overall survival 
of 14.9 
months was reported in a subgroup of patients treated with 5-FU and 
leucovorin 
plus oxaliplatin 14 but results from randomized trials comparing standard 
5-FU 
and leucovorin with the combination with oxaliplatin are not yet 
available. 
 
The most frequent side effect that we observed was mild (grade 1 or 2) 
oxaliplatin neurotoxicity, characterized by peripheral paresthesia, 
hypersensitivity 
to cold, or pharyngolaryngeal dysesthesia in 21 patients. We did not see 
any 
grade 3-4 neurologic toxicities, which are reported in other series in 
which 
oxaliplatin alone induced 14% to 23% of grade 3 neurotoxicities and 4% to 
8% of 
grade 4 neurotoxicities.7 The timing of the cycles has been always 
correct, with 
a median interval between cycles of 21 days (range, 21-71 days) because 
no 
significant hematologic toxicity was observed. Because quality of life is 
considered to be one of the most important targets of palliative 
chemotherapy 
for advanced cancer, oxaliplatin in combination with 5-FU may at least 
fulfill 
this important goal. In conclusion, oxaliplatin is a promising agent when 
given 
in combination with 5-FU or in a chronomodulated setting for treatment of 
advanced colorectal cancer. 
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